市場調査レポート

男性不妊医療の世界市場(技法・地域別) - 市場規模、シェア、世界動向、企業プロフィール、需要、考察、分析、調査、レポート、機会、セグメンテーションおよび予測

Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020

発行 Allied Market Research 商品コード 305978
出版日 ページ情報 英文 80 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
男性不妊医療の世界市場(技法・地域別) - 市場規模、シェア、世界動向、企業プロフィール、需要、考察、分析、調査、レポート、機会、セグメンテーションおよび予測 Global Male Infertility Market (Techniques and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2012 - 2020
出版日: 2014年04月01日 ページ情報: 英文 80 Pages
概要

1年の避妊手段を取らない性交渉期間を経過しても女性パートナーを受胎させられない男性能力の障害と定義される男性不妊症は、不妊症全体の2割を占め、生活習慣の変化、加齢、環境などの要因を主な背景に今後も増加する傾向にあり、その関連市場は今後4.9%の複合年間成長率から2020年には3億150万ドル規模に達する見込みです。

当レポートでは、男性不妊医療の世界市場に注目し、今後の価額推移を技法および地域別に分析・予測するほか、発展の推進・抑制要因、技術研究動向、競合環境、主要参入企業などについての最新情報を集めています。

第1章 イントロダクション

  • 主要成果
  • 調査方法
    • 二次情報調査
    • 一次情報取材
    • 分析ツールおよびモデル

第2章 エグゼクティブサマリー

第3章 市場規模測定

  • 市場の定義
    • 不妊医療についての基礎知識
      • 外科手術
        • 精索静脈瘤切除
        • その他の外科手術法
      • 性交渉時の問題に対する療法
        • 勃起障害
        • 早漏
      • ホルモン療法
        • ホルモン剤
        • 非ホルモン剤
      • 生殖補助医療(ART:assisted reproductive technology)
        • 精巣(睾丸)細針吸引生検(FNA:fine-needle aspiration)
        • 顕微鏡下精巣上体精子採取(MESA:microsurgical epididymal sperm aspiration)
        • 精巣内精子採取(TESE:testicular sperm extraction)
        • 精巣内精子吸引(TESA:testicular sperm aspiration)
      • 逆行性射精および射出障害の治療
      • 切除精管再生(精管吻合)
      • 「精管切除術」対「生殖補助医療」
  • 男性不妊医療市場推進要因
    • 生活習慣問題
    • 環境ファクター
    • 技術の進歩
    • 物理的原因
    • 不妊率の上昇
    • 高齢化
  • 男性不妊医療市場抑制要因
    • 度重なる治療失敗の影響
    • 社会的禁忌
  • 課題と機会
    • 医療ツアー
    • 認知度向上が市場成長につながることも
  • 需要分析
    • 不妊カップルのレベル(男女比)
    • 不妊診断を選択するカップル数
    • 体外受精治療(IVF)下にある人口総数
    • 体外受精治療の成功率
  • 男性不妊診断の市場規模
    • 世界市場 - 治療法別
    • 不妊治療法の世界市場 - 地域別
    • 男性不妊治療の世界市場規模

第4章 考察と対処法 - 男性不妊と体外受精

  • 男性不妊の原因
  • 男性不妊の評価
  • 精液解析
    • 実験室試験
    • 血液検査
    • 遺伝子検査
    • その他の試験
  • 男性不妊の治療
    • 生殖器閉塞
    • 性腺刺激ホルモン治療
    • 精索静脈瘤
    • その他
  • 男性不妊症に対する生殖補助医療
    • 体外受精
    • 卵細胞質内精子注入法(ICSI)
    • 精巣内精子採取
    • 生殖補助医療の制約
    • 不妊治療中の精神的支援

第5章 精液解析法 - 市場規模および分析

  • DNA断片化解析
    • イントロダクション
    • DNA断片化解析を実施する時期と理由
    • 試験結果の一貫性と精度、および補助医療技法選定の重要性
    • 精子DNA解析に利用できる試験法
      • 精子核クロマチン構造解析(SCSA:sperm chromatin structure assay)
      • TUNEL解析
      • ハロー試験
      • コメット解析
      • 原因不明不妊の治療
    • DNA検査の利点
    • 精子DNA損傷と生殖結果
    • 制約
    • 男性不妊DNA断片化解析の世界市場 - 地域別:2012-2020年(単位:100万ドル)
  • 酸化ストレス分析
    • 活性酸素誘発DNA損傷およびアポトーシス
    • 酸化ストレスの理由
    • 生活習慣の変化
      • アルコール摂取
      • 喫煙
      • 心理的ストレス
    • 加齢
    • 感染 - 男性副生殖腺感染症
    • 環境ファクター
      • 電磁放射線
      • 毒物・薬物
      • 医原性因子
      • 化学療法・薬剤
      • 精索静脈瘤
    • 酸化ストレス分析を実施する時期と理由
    • 試験結果の一貫性と精度、および補助医療技法選定の重要性
    • 酸化ストレス分析に利用できる試験法
      • 化学発光測定
      • 脂質過酸化反応マーカー
      • 酸化DNA損傷測定
      • その他の活性酸素測定法
    • 男性不妊酸化ストレス分析の世界市場 - 地域別:2012-2020年(単位:100万ドル)
  • 精子進入分析
    • 試験結果の一貫性と精度、および補助医療技法選定の重要性
      • 試験の理由
      • 精子進入検査
      • 精子粘液進入検査
      • 精子進入分析
    • 男性不妊精子進入分析の世界市場 - 地域別:2012-2020年(単位:100万ドル)
  • コンピューター支援精液解析(CASA)
    • 試験結果の一貫性と精度、および補助医療技法選定の重要性
    • コンピューター支援精液解析の機能
    • コンピューター支援精液解析の世界市場 - 地域別:2012-2020年(単位:100万ドル)
  • 精子凝集試験
    • 試験結果の一貫性と精度、および補助医療技法選定の重要性
      • MAR試験
      • 免疫ビーズ法
      • 診断
    • 男性不妊精子凝集試験の世界市場 - 地域別:2012-2020年(単位:100万ドル)
  • 顕微鏡検査
    • 試験結果の一貫性と精度、および補助医療技法選定の重要性
      • 精子濃度
    • 男性不妊顕微鏡検査の世界市場 - 地域別:2012-2020年(単位:100万ドル)
  • その他
    • 試験結果の一貫性と精度、および補助医療技法選定の重要性
    • その他男性不妊医療の世界市場 - 地域別:2012-2020年(単位:100万ドル)

第6章 男性不妊医療の世界市場 - 地域別(2012-2020年)

  • 北米
  • 欧州
  • アジア太平洋州
  • その他の地域

第7章 企業プロフィール(企業概要、寸見、事業成績)

  • EMD Serono, Inc.
  • Cadila Healthcare Ltd.(ZydusCadila group)
  • ASKA pharmaceuticals, Inc.
  • Intas pharmaceuticals Ltd.
  • Pantarhei Bioscience B.V.
  • Cordex Pharma, Inc.
  • Halotech DNA SL
  • SCSA diagnostics, Inc.
  • Andrology solutions
  • Access Pharmaceuticals, Inc.
目次
Product Code: ME 14241

The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 4.9% during 2013-2020. Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels.

The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient. The repeated failures would compel most patients to discontinue the treatment. The other limitation is the social taboo. Out of 32-40% infertile men, only 15% of the men opt for the treatment for infertility due to the embarrassment, guilt, etc.

The opportunity driving the market is medical tourism and increase in awareness about male infertility. The treatment for male infertility is expensive; however, the cost of the treatment is expected to decrease with the advancement in treatment technologies. The other factor that may drag the prices lower would be the patients*ス-expectations for cost effective treatments. These factors would drive the male infertility market.

Male Infertility Semen Analysis Techniques Market Analysis

The male infertility techniques market is segmented into DNA fragmentation technique, oxidative stress analysis, microscopic examination, sperm penetration assay, sperm agglutination, computer assisted semen analysis and others. The DNA fragmentation is an emerging technique; it is currently being used as a routine technique in the developed nations. However, it is yet to come into routine analysis in the labs of the developing nations, as cost being the major hindrance in their usage.

Male Infertility Geographic Market Analysis

The male infertility market is segmented into North America, Europe, Asia Pacific and RoW. The North American market is the dominating market with the highest revenue, followed by the Asia pacific market. The Asia pacific market and RoW region are expected to have the highest potential for growth in the analysis period. This is due to the adoption of the new techniques in the treatment of male infertility, such as DNA fragmentation and computer assisted semen analysis. The growth in these regions can also be accredited to the rising infertility levels and awareness about infertility and its treatments.

Competitive Landscape

The companies profiled in this report are ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, Cordex Pharma, Inc., Merck Serono, Halotech DNA SL, SCSA diagnostics, Andrology Solutions.

High Level Analysis

The report analyzes various techniques used in the treatment of male infertility problems. The microscopic examination segment occupied the highest share in the male infertility techniques market in 2012. This is due to its routine use in the diagnosing of male infertility problems, as it is a basic test. DNA fragmentation segment is expected to have the highest market share by 2020, due to its accurate test results that help physicians to diagnose exact issues and suggest appropriate treatments that lead couples to conceive.

KEY BENEFITS

The report provides detailed analysis about the driving and limiting factors of the male infertility market, which would give a deeper understanding of the subject and help in taking actionable decisions.

The market size of the male infertility diagnostic and treatments will help in analyzing the market, thus helping the stakeholders understand opportunities in the male infertility market

Market share analysis of both male and female infertility treatments that allow the decision makers to gauge the market strength and make profitable investments

The report analyzes the market condition in a comprehensive and quantitative manner and forecast market trends and techniques used in male infertility treatments

Reason for the Study

  • To study the various techniques used to treat male infertility
  • To identify the benefits of the new techniques over the conventional techniques
  • To study the treatment trends in various geographic regions

KEY DELIVERABLES

The global male infertility market is segmented based on techniques and geography.

MARKET BY TECHNIQUES

  • DNA Fragmentation Technique
  • Oxidative Stress Analysis
  • Microscopic Examination
  • Sperm Penetration Assay
  • Sperm Agglutination
  • Computer Assisted Semen Analysis
  • Others

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • RoW

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Key deliverables
  • 1.2. Research Methodology
    • 1.2.1. Secondary research
    • 1.2.2. Primary research
    • 1.2.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

CHAPTER 3 - MARKET SIZING

  • 3.1. Market definition
    • 3.1.1. Basics of infertility treatment techniques
      • 3.1.1.1. Surgery
        • 3.1.1.1.1. VARICOCELECTOMY
        • 3.1.1.1.2. OTHER SURGICAL METHODS
      • 3.1.1.2. Treatment for problems in intercourse.
        • 3.1.1.2.1. ERECTILE DYSFUNCTION
        • 3.1.1.2.2. PREMATURE EJACULATION
      • 3.1.1.3. Hormone treatment
        • 3.1.1.3.1. HORMONAL AGENTS
        • 3.1.1.3.2. NON-HORMONAL AGENTS
      • 3.1.1.4. ART technology
        • 3.1.1.4.1. TESTICULAR FINE NEEDLE ASPIRATION
        • 3.1.1.4.2. MICROSURGICAL EPIDIDYMAL SPERM ASPIRATION
        • 3.1.1.4.3. TESTICULAR SPERM EXTRACTION
        • 3.1.1.4.4. TESTICULAR SPERM ASPIRATION
      • 3.1.1.5. Treatment for Retrograde Ejaculation and Failure of Emission
      • 3.1.1.6. Vasectomy Reversal (Vasovasostomy)
      • 3.1.1.7. Reversal vasectomy versus ART
  • 3.2. Male infertility market drivers
    • 3.2.1. Life style issues
    • 3.2.2. Environmental factors
    • 3.2.3. Advancement in technology
    • 3.2.4. Physical causes
    • 3.2.5. Rise in infertility rates
    • 3.2.6. Age
  • 3.3. Male infertility market restraints
    • 3.3.1. Impact of repeated failures in treatments
    • 3.3.2. Social taboos
  • 3.4. Challenges and opportunities
    • 3.4.1. Medical tourism
    • 3.4.2. Increased awareness level may lead to market growth
  • 3.5. Demand analysis
    • 3.5.1. Level of infertility couples (males versus female)
    • 3.5.2. Number of couple who opt for infertility diagnostics
    • 3.5.3. Total population under IVF treatment
    • 3.5.4. Success rate for IVF treatment
  • 3.6. Male versus Female infertility treatment market
  • 3.7. Market size for male infertility diagnostics market
    • 3.7.1. Global male infertility market by techniques
    • 3.7.2. Global male infertility techniques market by geography
    • 3.7.3. Market size for male infertility treatments market

CHAPTER 4 - CONSIDERATIONS AND PROCESS - MALE INFERTILITY & IVF TREATMENT

  • 4.1. Causes of male infertility
  • 4.2. Evaluation of male infertility
  • 4.3. Semen Analysis
    • 4.3.1. Lab testing
    • 4.3.2. Blood tests
    • 4.3.3. Genetic tests
    • 4.3.4. Other tests
  • 4.4. Treatments of male infertility
    • 4.4.1. Reproductive tract blockage
    • 4.4.2. Gonadotropin treatment
    • 4.4.3. Varicocele
    • 4.4.4. Others
  • 4.5. ART for male infertility
    • 4.5.1. IVF
    • 4.5.2. ICSI
    • 4.5.3. TESE (testicular extraction of sperm)
    • 4.5.4. Limitation of ART
    • 4.5.5. Emotional support during infertility treatment

CHAPTER 5 - SEMEN ANALYSIS TECHNIQUES - MARKET SIZE AND ANALYSIS

  • 5.1. DNA fragmentation
    • 5.1.1. Introduction
    • 5.1.2. When and why is DNA fragmentation conducted
    • 5.1.3. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    • 5.1.4. Available tests for sperm DNA fragmentation
      • 5.1.4.1. SCSA (Sperm chromatin structure assay)
      • 5.1.4.2. TUNEL assay
      • 5.1.4.3. Halo test
      • 5.1.4.4. Comet assay
      • 5.1.4.5. Unexplained infertility treatment
    • 5.1.5. DNA testing benefits
    • 5.1.6. Sperm DNA damage and reproductive outcomes
    • 5.1.7. Limitations
    • 5.1.8. Global male infertility DNA fragmentation market by geography, 2012-2020($Million)
  • 5.2. Oxidative stress analysis
    • 5.2.1. ROS induced DNA damage and apoptosis
    • 5.2.2. Reasons for oxidative stress
    • 5.2.3. Lifestyle changes
      • 5.2.3.1. Consumption of alcohol
      • 5.2.3.2. Smoking
      • 5.2.3.3. Psychological stress
    • 5.2.4. Aging
    • 5.2.5. Infection - MAGI (Male accessory sex gland infection)
    • 5.2.6. Environmental Factors
      • 5.2.6.1. Electromagnetic radiation
      • 5.2.6.2. Toxins and chemicals
      • 5.2.6.3. Iatrogenic
      • 5.2.6.4. Chemotherapy and Drugs
      • 5.2.6.5. Varicocele
    • 5.2.7. When and why oxidative stress analysis test is conducted
    • 5.2.8. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    • 5.2.9. Available tests for Oxidative stress analysis
      • 5.2.9.1. Chemiluminescence
      • 5.2.9.2. Lipid peroxidation markers
      • 5.2.9.3. Measurement of oxidative DNA damage
      • 5.2.9.4. Other methods of ROS measurement
    • 5.2.10. Global male infertility oxidative stress market by geography, 2012-2020($Million)
  • 5.3. Sperm penetration assay
    • 5.3.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      • 5.3.1.1. The reasons for the tests
      • 5.3.1.2. Sperm Penetration Tests
      • 5.3.1.3. Sperm Mucus Penetration Test
      • 5.3.1.4. Sperm Penetration Assay
    • 5.3.2. Global male infertility sperm penetration assay market by geography, 2012-2020($Million)
  • 5.4. Computer assisted semen analysis
    • 5.4.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    • 5.4.2. Functions of computer assisted sperm analysis
    • 5.4.3. Global male infertility CASA market by geography, 2012-2020($Million)
  • 5.5. Sperm Agglutination
    • 5.5.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      • 5.5.1.1. MAR test
      • 5.5.1.2. Immunobead Binding
      • 5.5.1.3. Diagnosis
    • 5.5.2. Global male infertility sperm agglutination market by geography, 2012-2020($Million)
  • 5.6. Microscopic examination
    • 5.6.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
      • 5.6.1.1. Sperm concentration
    • 5.6.2. Global male infertility microscopic examination market by geography, 2012-2020($Million)
  • 5.7. Others
    • 5.7.1. Consistency and accuracy of data generated from the tests and importance in deciding the ART treatments
    • 5.7.2. Global male infertility others market by geography, 2012-2020($Million)

CHAPTER 6 - GLOBAL MALE INFERTILITY MARKET BY GEOGRAPHY

  • 6.1. North America
    • 6.1.1. North American male infertility market, 2012-2020
  • 6.2. Europe
    • 6.2.1. Europe male infertility market, 2012-2020
  • 6.3. Asia pacific
    • 6.3.1. Asia pacific male infertility market, 2012-2020
  • 6.4. RoW
    • 6.4.1. RoW male infertility market, 2012-2020

CHAPTER 7 - COMPANY PROFILES

  • 7.1. EMD Serono, Inc.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Business performance
  • 7.2. Cadila Healthcare Ltd.(ZydusCadila group)
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
  • 7.3. ASKA pharmaceuticals, Inc.
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Business performance
    • 7.3.4. Strategic moves and developments
  • 7.4. Intas pharmaceuticals Ltd.
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Business performance
  • 7.5. Pantarhei Bioscience B.V.
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
  • 7.6. Cordex Pharma, Inc.
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
  • 7.7. Halotech DNA SL
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Financial Performance
  • 7.8. SCSA diagnostics, Inc.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Financial Performance
  • 7.9. Andrology solutions
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
  • 7.10. Access Pharmaceuticals, Inc.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Business performance

LIST OF TABLES:

  • TABLE 1: GLOBAL MALE INFERTILITY TECHNIQUES MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 2: GLOBAL MALE INFERTILITY MARKET BY TECHNIQUES,2012-2020 ($MILLION)
  • TABLE 3: GLOBAL MALE INFERTILITY TECHNIQUES MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 4: GLOBAL MALE INFERTILITY DNA FRAGMENTATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 5: GLOBAL MALE INFERTILITY OXIDATIVE STRESS MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 6: GLOBAL MALE INFERTILITY SPERM PENETRATION ASSAY MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 7: GLOBAL MALE INFERTILITY CASA MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 8: GLOBAL MALE INFERTILITY SPERM AGGLUTINATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 9: GLOBAL MALE INFERTILITY MICROSCOPIC EXAMINATION MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 10: GLOBAL MALE INFERTILITY OTHERS MARKET BY GEOGRAPHY, 2012-2020 ($MILLION)
  • TABLE 11: NORTH AMERICAN MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
  • TABLE 12: EUROPE MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
  • TABLE 13: ASIA PACIFIC MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
  • TABLE 14: ROW MALE INFERTILITY MARKET, 2012-2020 ($MILLION)
  • TABLE 15: EMD SERONO, INC BUSINESS SNAPSHOT
  • TABLE 16: ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
  • TABLE 17: ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
  • TABLE 18: ASKA PHARMACEUTICALS, INC BUSINESS SNAPSHOT
  • TABLE 19: PANTARHEI BIOSCIENCE B.V. BUSINESS SNAPSHOT
  • TABLE 20: CORDEX PHARMA, INC. BUSINESS SNAPSHOT
  • TABLE 21: HALOTECH DNA SL BUSINESS SNAPSHOT
  • TABLE 22: SCSA DIAGNOSTICS, INC. BUSINESS SNAPSHOT
  • TABLE 23: ANDROLOGY SOLUTIONS BUSINESS SNAPSHOT
  • TABLE 24: ACCESS PHARMACEUTICALS, INC. BUSINESS SNAPSHOT

LIST OF FIGURES:

  • FIG. 1: TYPES OF MALE DISORDERS
  • FIG. 2: CONVENTIONAL, CURRENT AND ADVANCED TREATMENTS FOR MALE INFERTILITY
  • FIG. 3: PERCENTAGE OF RETRIEVALS WHICH RESULTED IN LIVE BIRTHS AMONG COUPLES WITH DIAGNOSED MALE FACTOR INFERTILITY USING IVF WITH ICSI (2010)
  • FIG. 4: MARKET SHARE OF MALE AND FEMALE INFERTILITY TREATMENT 2013 AND 2020
  • FIG. 5: MARKET SHARE OF MALE VERSUS FEMALE INFERTILITY TREATMENT MARKET (PERCENTAGE SHARE - 2013 TO 2020)
  • FIG. 6: MARKET SIZE FOR MALE INFERTILITY TREATMENTS MARKET, 2013 - 2020 ($MILLION)
  • FIG. 7: LEVEL OF FRAGMENTED DNA
  • FIG. 8: NUMBER OF DELIVERIES WITH OR WITHOUT MEASURING FRAGMENTATION
  • FIG. 9: SALES BY REGION, 2012
  • FIG. 10: HALOTECH DNA SL REVENUE BY YEAR (2012 - 2013)
  • FIG. 11: SCSA DIAGNOSTICS, INC. REVENUE BY YEAR (2012 - 2013)
  • FIG. 12: ACCESS PHARMACEUTICALS, INC. REVENUE BY YEAR (2011 - 2012)
Back to Top